Side effects of retinoid therapy on the quality of vision

Open access

Abstract

Retinoids are compounds chemically related to vitamin A, which are frequently used in dermatological practice (1). They are characterized by numerous mechanisms of action leading to normalization of keratinocyte proliferation and maturation. They have anti-seborrhoeic, immunomodulatory and anti-inflammatory effects (1, 2). A number of side effects to retinoid treatment have been recorded; one group of such side effects relates to eyes and vision. Dry eye syndrome and blepharoconjunctivitis are the most common side effects, appearing in 20-50 % of patients treated with retinoids. They often contribute to the occurrence of other side-effects such as eye discomfort and contact lens intolerance. Due to the widespread use in clinical practice, the adverse effects, including ocular side effects, should be studied. To confirm the variety of adverse effects of retinoids, several case reports of rare side-effects are presented.

1. W. H. C. Burgdorf, G. Plewig, H. H. Wolff, M. Landthale and O. Braun-Falco, Braun-Falco’s Dermatology, Springer Verlag, Berlin-Heidelberg 2009.

2. B. Bergler-Czop, Nowy Schemat Terapii Różnych Postaci Trądziku Oparty na Analizie Skórno-Śluzówkowych Objawów Ubocznych Stosowania Retinoidów oraz Stężeń Cytokin Prozapalnych - A New Therapy Scheme of Various Kinds of Acne Based on Skin-mucosal Side-effects of Retinoid Treatment and Pro-inflammatory Cytokines Levels, Ph. D. Thesis, Medical University of Silesia, Publisher Tekst, Katowice 2011.

3. E. Papakonstantinou, A. J. Aletras, E. Glass, P. Tsogas, A. Dionyssopoulos, J. Adjaye, S. Fimmel, P. Gouvousis, R. Herwig, H. Lehrach, C. C. Zouboulis and G. Karakiulakis, Matrix metalloproteinases of epithelial origin in facial sebum of patients with acne and their regulation by isotretinoin, J. Invest. Dermatol. 125 (2005) 673-684.

4. B. Bergler-Czop and L. Brzezińska-Wcisło, Pro-inflammatory cytokines in patients with various kinds of acne treated with isotretinoin, Postepy Dermatol. Alergol. 31 (2014) 21-28; DOI: 10.5114/ pdia.2014.40655.

5. L. Beckenbach, J. M. Baron, H. F. Merk, H. Löffler and P. M. Amann, Retinoid treatment of skin diseases, Eur. J. Dermatol. 25 (2015) 384-391; DOI: 10.1684/ejd.2015.2544.

6. S. C. On and J. Zeichner, Isotretinoin updates, Dermatol. Ther. 26 (2013) 377-389; DOI: 10.1111/dth.12084.

7. G. Carretero, M. Ribera, I. Belinchón, J. M. Carrascosa, L. Puig, C. Ferrandiz, L. Dehesa, D. Vidal, F. Peral, E. Jorquera, A. González-Quesada, C. Muñoz, J. Notario, F. Vanaclocha and J. C. Moreno, Psoriasis group of the AEDV. Guidelines for the use of acitretin in psoriasis. Psoriasis Group of the Spanish Academy of Dermatology and Venereology, Actas Dermosifiliogr. 104 (2013) 598-616; DOI: 10.1016/j.adengl.2013.01.001.

8. U. Cegieła, J. Folwarczna, R. Janiec and W. Janiec, Kompendium Farmakologii, Państwowy Zakład Wydawnictw Lekarskich Publishing, Warsaw 2012, pp. 400-402.

9. K. H. Dragnev, W. J. Petty, S. J. Shah, L. D. Lewis, C. C. Black, V. Memoli, W. C. Nugent, T. Hermann, A. Negro-Vilar, J. R. Rigas and E. Dmitrovsky, A proof-of-principle clinical trial of bexarotene in patients with non-small cell lung cancer, Clin. Cancer Res. 13 (2007) 1794-1800.

10. A. L. Zaenglein, A. L. Pathy, B. J. Schlosser, A. Alikhan, H. E. Baldwin, D. S. Berson, W. P. Bowe, E. M. Graber, J. C. Harper, S. Kang, J. E. Keri, J. J. Leyden, R. V. Reynolds, N. B. Silverberg, L. F. Stein Gold, M. M. Tollefson, J. S. Weiss, N. C. Dolan, A. A. Sagan, M. Stern, K. M. Boyer and R. Bhushan, Guidelines of care for the management of acne vulgaris, J. Am. Acad. Dermatol. (2016) in press; DOI: 10.1016/j.jaad.2015.12.037.

11. H. E. Baldwin, M. Nighland, B. Kendall, D. A. Mays, R. Grossman and J. Newburger, 40 years of topical tretinoin use in review, J. Drugs Dermatol. 12 (2013) 638-642.

12. G. Shiva, M. Somaye and J. M. Reza, Improved photostability, reduced skin permeation and irritation of isotretinoin by solid lipid nanoparticles, Acta Pharm. 62 (2012) 547-562; DOI: 10.2478/v10007-012-0032-z.

13. F. T. Fraunfelder, F. W. Fraunfelder and R. Edwards, Ocular side effects possibly associated with isotretinoin usage, Am. J. Ophthalmol. 132 (2001) 299-305; DOI: 10.1016/S0002-9394(01)01024-8.

14. A. Karalezli, M. Borazan, D. D.Altinors, R. Dursun, H. Kiyici and Y. A. Akova, Conjunctival impression cytology, ocular surface, and tear-film changes in patients treated with systemic isotretinoin, Cornea 28 (2009) 46-50; DOI: 10.1097/ICO.0b013e318183a396.

15. M. J. Ju, J. G. Shin, S. Hoshi, Y. Yasuno, B. H. Lee, S. Tang and T. J. Eom, Three-dimensional volumetric human meibomian gland investigation using polarization-sensitive optical coherence tomography, J. Biomed. Opt. 19 (2014) ID 030503; DOI: 10.1117/1.JBO.19.3.030503.

16. R. W. Lambert and R. E. Smith, Pathogenesis of blepharoconjunctivitis complicating 13-cis-retinoic acid (isotretinoin) therapy in a laboratory model, Invest. Ophthalmol. Vis. Sci. 29 (1988) 1559-1564.

17. W. D. Mathers, W. J. Shields, M. S. Sachde, W. M. Petroll and J. V. Jester, Meibomian gland morphology and tear osmolarity: changes with Accutane therapy, Cornea 10 (1991) 286-290.

18. M. Neudorfer, I. Goldshtein, O. Shamai-Lubovitz, G. Chodick, Y. Dadon and V. Shalev, Ocular adverse effects of systemic treatment with isotretinoin, Arch. Dermatol. 148 (2012) 803-808; DOI: 10.1001/archdermatol.2012.352.

19. T. Cumurcu, E. Sezer, R. Kilic and Y. Bulut, Comparison of dose-related ocular side effects during systemic isotretinoin administration, Eur. J. Ophthalmol. 19 (2009) 196-200.

20. M. Brelsford and T. C. Beute, Preventing and managing the side effects of isotretinoin, Semin. Cutan. Med. Surg. 27 (2008) 197-206; DOI: 10.1016/j.sder.2008.07.002.

21. P. A. Sieving, P. Chaudhry, M. Kondo, M. Provenzano, D. Wu, T. J. Carlson, R. A. Bush and D. A. Thompson, Inhibition of the visual cycle in vivo by 13-cis-retinoic acid protects from light damage and provides a mechanism for night blindness in isotretinoin therapy, Proc. Natl. Acad. Sci. USA 98 (2001) 1835-1840; DOI: 10.1073/pnas.98.4.1835.

22. S. P. Mollan, M. Woodcock, R. Siddiqi, J. Huntbach, P. Good and R. A. H. Scott, Does use of isotretinoin rule out a career in flying? Br. J. Ophthalmol. 90 (2006) 957-959; DOI: 10.1136/bjo.2006.092833.

23. J. Santodomingo-Rubido, E. Barrado-Navascués and M. J. Rubido-Crespo, Drug-induced ocular sideeffects with isotretinoin, Ophthalmic Physiol. Opt. 28 (2008) 497-501; DOI: 10.1111/j/1475-1313.2008.00590.x.

24. H. I. Onder, H. Turan, A. C. Kilic, M. Kaya and M. Tunc, Premacular hemorrhage due to isotretinoin use, Cutan. Ocul. Toxicol. 32 (2013) 170-172; DOI: 10.3109/15569527.2012.676121.

25. H. Gursoy, I. Cakmak, N. Yildirim and H. Basmak, Presumed isotretinoin-induced, concomitant autoimmune thyroid disease and ocular myasthenia gravis: a case report, Case Rep. Dermatol. 4 (2012) 256-260; DOI: 10.1159/000345680.

Acta Pharmaceutica

The Journal of Croatian Pharmaceutical Society

Journal Information


IMPACT FACTOR 2017: 1.071
5-year IMPACT FACTOR: 1.623

CiteScore 2017: 1.46

SCImago Journal Rank (SJR) 2017: 0.362
Source Normalized Impact per Paper (SNIP) 2017: 0.642

Cited By

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 205 205 34
PDF Downloads 81 81 15